Results 191 to 200 of about 231,111 (314)

Bufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression

Advanced Science, EarlyView.
Mechanisms of Bufalin‐Mediated Intervention in Breast Cancer. ABSTRACT Breast cancer incidence is rising globally, presenting challenges such as treatment side effects and drug resistance. Bufalin is a bufadienolides compound with potential anti‐cancer effects. This study shows that bufalin inhibits malignant proliferation of MDA‐MB‐231 and MCF‐7 cells
Siyu Guo, Xiaodong Chen, Haojia Wang, Jiying Zhou, Peiying Lu, Jiangying Liu, Keyan Chai, Jingyuan Zhang, Siyun Yang, Shan Lu, Yifei Gao, Zhengsen Jin, Xiaoyu Tao, Zhongdong Hu, Qinglin Li, Jiarui Wu   +15 more
wiley   +1 more source

Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies. [PDF]

Cancers (Basel)
Tsagkaraki I, Gannon I, Rampotas A, Singh D, Roddy H, Ottaviani D, Roddie C.   +6 more
europepmc   +1 more source

Tailoring Vascular‐Immune Homeostasis via Manganese‐DNA Complex‐Armed Immunogenic Extracellular Vesicles for Pancreatic Cancer Immunotherapy

Advanced Science, EarlyView.
This study demonstrates that Mn2⁺–tumor DNA complexes encapsulated in dendritic cell (DC)– derived immunogenic extracellular vesicles (EVDC@Mn‐DNA) act as a DC‐specific cGAS– STING activator. EVDC@Mn‐DNA treatment enhances intratumoral DC activation, improves tumor vascular function, promotes CD8⁺ T cell activity, and suppresses pancreatic tumor growth,
Xue Jiang, Lihuan Shang, Xiaochun Chen, Xiangzhan Kong, Xiaojuan Wang, Linjia Jiang, Huiying Zhao, Yafeng Zhu, Cheng Huang, Shiyi Deng, Rui Zhang, Minghui Wang, Haoming Lin, Ping‐Pui Wong   +13 more
wiley   +1 more source

The 15-year bibliometric landscape of glioblastoma vaccines: Emergence of combinatorial immunotherapy. [PDF]

Hum Vaccin Immunother
Long Z, Liu K.
europepmc   +1 more source

Strawberry Notch 1 Acts as a Transcriptional Regulator Driving Oncogenic Programs in Liver Carcinogenesis

Advanced Science, EarlyView.
This study reports that SBNO1 protein is upregulated in several cancer entities. SBNO1 protein interacts with the basal transcription factor TFIID via TAF4, enabling its recruitment to transcription start sites and the modulation of target gene expression.
Sarah Fritzsche, Raisatun Nisa Sugiyanto, Kira Gür, Alina Krumme, Maxime Le Marois, Angelika Fraas, Aslihan Inal, Mario Huerta, Vanessa Henriques, Eva Eiteneuer, Thomas Albrecht, Alphonse Charbel, Michael T. Dill, Carsten Sticht, Carolina De La Torre, Stefan Pusch, Arianeb Mehrabi, Kai Breuhahn, Junfang Ji, Peter Schirmacher, Benjamin Goeppert, Stephanie Roessler   +21 more
wiley   +1 more source

Cost-Effectiveness of Oral Immunotherapy Treatments vs No Treatment for Peanut Allergy in Children.

JAMA Netw Open
Huang L, Lloyd M, Franz A, Loke P, O'Sullivan M, Gold M, Quinn P, Tang MLK, Dalziel K.   +8 more
europepmc   +1 more source

Complete locoregional response to radiotherapy and pembrolizumab in an elderly and frail patient with oropharyngeal squamous cell carcinoma: A case report. [PDF]

Medicine (Baltimore)
Zoboli FB, Mosca M, Gagliano A, Laghi V, Siepe G, Rihawi K, Nobili E, Filippini DM.   +7 more
europepmc   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy. [PDF]

Cancer Immunol Immunother
Canaslan K, Moeini Nia F, Baez M, Abolhassani H, Ridge N, Bou Zerdan M, Marks J, Rangoonwala H, Jahanbin B, Emami AH, O'Reilly K, Gökmen-Polar Y, Badve SS, Xu C, Hao Y, Sharma A, Upadhya S, Galateau Salle F, Pan K, El Olsta B, Shin DM, Ardeshir-Larijani F.   +21 more
europepmc   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source